To the Editor.
—I have read with interest the article by Alarcón et al,1 as it showed that the length of albendazole therapy for parenchymal brain cysticercosis could be considerably shortened without lessening its efficacy. The authors did not state, however, how the 3-day course of albendazole treatment was chosen. Was it chosen on an empirical basis? If so, a larger number of patients was needed to support their findings.Albendazole is an imidazole with intense antiparasitic properties that has largely replaced praziquantel as the drug of choice for parenchymal brain cysticercosis.2-4 The initial length of 30 days of albendazole therapy for neurocysticercosis5 was settled according to that previously used for the treatment of human hydatidosis.6 When treating patients with cysticercosis, however, two observations suggested that the therapeutic effect of the drug occurred far before the full course of 30 days was completed: first, most patients
Del Brutto OH. Albendazole Therapy for Neurocysticercosis. Arch Neurol. 1990;47(12):1278. doi:10.1001/archneur.1990.00530120018003
Neurology in JAMA: Read the Latest
Customize your JAMA Network experience by selecting one or more topics from the list below.